B. Riley Brokers Lower Earnings Estimates for G1 Therapeutics Inc (NASDAQ:GTHX)

Share on StockTwits

G1 Therapeutics Inc (NASDAQ:GTHX) – Analysts at B. Riley lowered their FY2023 EPS estimates for shares of G1 Therapeutics in a report released on Tuesday, August 13th. B. Riley analyst H. Polishetty now expects that the company will earn $1.56 per share for the year, down from their previous estimate of $1.73.

Several other research analysts have also commented on the stock. Cowen restated a “buy” rating on shares of G1 Therapeutics in a report on Tuesday, June 18th. ValuEngine upgraded shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. JPMorgan Chase & Co. upgraded shares of G1 Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $38.00 to $45.00 in a report on Thursday, August 8th. BidaskClub upgraded shares of G1 Therapeutics from a “hold” rating to a “buy” rating in a report on Monday, June 24th. Finally, Zacks Investment Research lowered shares of G1 Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 16th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $61.00.

NASDAQ GTHX opened at $37.40 on Wednesday. G1 Therapeutics has a one year low of $13.87 and a one year high of $69.57. The company’s 50 day moving average price is $27.71 and its 200 day moving average price is $21.84. The firm has a market capitalization of $1.50 billion, a price-to-earnings ratio of -14.61 and a beta of 2.66.

G1 Therapeutics (NASDAQ:GTHX) last posted its quarterly earnings results on Wednesday, August 7th. The company reported ($0.82) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.73) by ($0.09).

Institutional investors and hedge funds have recently bought and sold shares of the company. Bank of Montreal Can raised its stake in shares of G1 Therapeutics by 93,600.0% during the second quarter. Bank of Montreal Can now owns 2,811 shares of the company’s stock valued at $86,000 after purchasing an additional 2,808 shares during the period. Legal & General Group Plc grew its position in shares of G1 Therapeutics by 20.0% during the fourth quarter. Legal & General Group Plc now owns 4,060 shares of the company’s stock worth $78,000 after buying an additional 676 shares in the last quarter. BNP Paribas Arbitrage SA grew its position in shares of G1 Therapeutics by 1,539.2% during the first quarter. BNP Paribas Arbitrage SA now owns 5,098 shares of the company’s stock worth $85,000 after buying an additional 4,787 shares in the last quarter. NumerixS Investment Technologies Inc acquired a new stake in shares of G1 Therapeutics during the first quarter worth approximately $98,000. Finally, Metropolitan Life Insurance Co. NY grew its position in shares of G1 Therapeutics by 413.4% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 7,665 shares of the company’s stock worth $147,000 after buying an additional 6,172 shares in the last quarter. Institutional investors own 73.58% of the company’s stock.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Featured Story: Derivative

Earnings History and Estimates for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

B. Riley Brokers Lower Earnings Estimates for G1 Therapeutics Inc
B. Riley Brokers Lower Earnings Estimates for G1 Therapeutics Inc
Critical Analysis: Progress Software  and Mobivity
Critical Analysis: Progress Software and Mobivity
Hydro One’s  Market Perform Rating Reaffirmed at Raymond James
Hydro One’s Market Perform Rating Reaffirmed at Raymond James
National Bank Financial Boosts Heroux Devtek  Price Target to C$23.00
National Bank Financial Boosts Heroux Devtek Price Target to C$23.00
National Bank Financial Raises Dream Global REIT  Price Target to C$18.00
National Bank Financial Raises Dream Global REIT Price Target to C$18.00
First Quantum Minerals  Earns Sector Perform Rating from National Bank Financial
First Quantum Minerals Earns Sector Perform Rating from National Bank Financial


 
© 2006-2019 Zolmax.